ECSP088459A - Formulaciones de proteina de fusion de inmunoglobulina - Google Patents
Formulaciones de proteina de fusion de inmunoglobulinaInfo
- Publication number
- ECSP088459A ECSP088459A EC2008008459A ECSP088459A ECSP088459A EC SP088459 A ECSP088459 A EC SP088459A EC 2008008459 A EC2008008459 A EC 2008008459A EC SP088459 A ECSP088459 A EC SP088459A EC SP088459 A ECSP088459 A EC SP088459A
- Authority
- EC
- Ecuador
- Prior art keywords
- fusion protein
- compositions
- immunoglobulin fusion
- protein formulations
- lyophilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a composiciones de proteínas de fusión de Ig, especialmente composiciones que incluyen una proteína de fusión de Ig, un agente de volumen, un disacárido, un tensioactivo, y un amortiguador. En un aspecto, estas composiciones son estables bajo almacenamiento a largo plazo o al menos un ciclo de congelación/descongelación. La invención también proporciona métodos de preparación de las composiciones de proteína de fusión de Ig. En un aspecto, las composiciones de la invención son liofilizadas. En un aspecto adicional, las composiciones son liofilizadas por un proceso que incluye una etapa de recocido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73927105P | 2005-11-22 | 2005-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088459A true ECSP088459A (es) | 2008-06-30 |
Family
ID=37781927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008459A ECSP088459A (es) | 2005-11-22 | 2008-05-19 | Formulaciones de proteina de fusion de inmunoglobulina |
Country Status (14)
Country | Link |
---|---|
US (2) | US20070237758A1 (es) |
EP (1) | EP1951305A1 (es) |
JP (1) | JP2009516692A (es) |
KR (1) | KR20080071192A (es) |
CN (1) | CN101312744A (es) |
AU (1) | AU2006318583A1 (es) |
BR (1) | BRPI0618893A2 (es) |
CA (1) | CA2630115A1 (es) |
CR (1) | CR10012A (es) |
EC (1) | ECSP088459A (es) |
NO (1) | NO20082133L (es) |
RU (1) | RU2008118166A (es) |
SV (1) | SV2009002911A (es) |
WO (1) | WO2007062040A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2612937C (en) * | 2005-07-22 | 2014-05-06 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
CL2008000058A1 (es) * | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
WO2008101179A2 (en) * | 2007-02-16 | 2008-08-21 | Wyeth | Use of sucrose to suppress mannitol-induced protein aggregation |
ES2436779T3 (es) * | 2007-11-12 | 2014-01-07 | Ares Trading S.A. | Formulaciones para proteínas de fusión TACI-inmunoglobulina |
UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
EP2442798A4 (en) * | 2009-06-18 | 2013-03-13 | Wyeth Llc | LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS |
CN101693016B (zh) * | 2009-11-02 | 2012-07-25 | 北京美福源生物医药科技有限公司 | 通用的注射用重组人血清白蛋白融合蛋白制剂配方 |
JP2013510158A (ja) | 2009-11-03 | 2013-03-21 | グリフオルス・セラピユーテイクス・インコーポレーテツド | α‐1プロテイナーゼインヒビターのための組成物、方法およびキット |
WO2011066291A2 (en) * | 2009-11-24 | 2011-06-03 | Talecris Biotherapeutics, Inc. | Lyophilization methods, compositions, and kits |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
CN105435222B (zh) * | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN104940926B (zh) * | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
GB201513010D0 (en) | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
MA42657A (fr) | 2015-08-18 | 2018-06-27 | Regeneron Pharma | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines |
CN112739323A (zh) | 2018-05-10 | 2021-04-30 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
WO2020021330A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
CN110607554B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备药物或药物中间体单晶或无定型物的方法 |
CN111195349B (zh) * | 2018-11-16 | 2023-02-24 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干粉制剂 |
BR112021012675A2 (pt) * | 2019-01-06 | 2021-09-28 | Endo Global Aesthetics Limited | Formulação, formulação liofilizada, formulação reconstituída e kit |
US11498969B2 (en) | 2019-01-31 | 2022-11-15 | Sanofi Biotechnology | Compositions and methods for treating juvenile idiopathic arthritis |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
EP1516628B1 (en) * | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP3900664B2 (ja) * | 1997-09-26 | 2007-04-04 | 株式会社ニコン | 顕微鏡 |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
BR0008405B1 (pt) * | 1999-02-22 | 2014-04-22 | Baxter Int | Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa |
WO2000066160A1 (fr) * | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation |
AU2003219958B2 (en) * | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
EP1720519A1 (en) * | 2004-03-04 | 2006-11-15 | Wyeth | Lyophilization method to improve excipient crystallization |
-
2006
- 2006-11-21 KR KR1020087015109A patent/KR20080071192A/ko not_active Application Discontinuation
- 2006-11-21 CA CA002630115A patent/CA2630115A1/en not_active Abandoned
- 2006-11-21 BR BRPI0618893-1A patent/BRPI0618893A2/pt not_active IP Right Cessation
- 2006-11-21 US US11/562,299 patent/US20070237758A1/en not_active Abandoned
- 2006-11-21 EP EP06838185A patent/EP1951305A1/en not_active Withdrawn
- 2006-11-21 AU AU2006318583A patent/AU2006318583A1/en not_active Abandoned
- 2006-11-21 WO PCT/US2006/045059 patent/WO2007062040A1/en active Application Filing
- 2006-11-21 CN CNA2006800437873A patent/CN101312744A/zh active Pending
- 2006-11-21 JP JP2008541422A patent/JP2009516692A/ja not_active Withdrawn
- 2006-11-21 RU RU2008118166/15A patent/RU2008118166A/ru not_active Application Discontinuation
-
2008
- 2008-05-07 NO NO20082133A patent/NO20082133L/no not_active Application Discontinuation
- 2008-05-19 EC EC2008008459A patent/ECSP088459A/es unknown
- 2008-05-22 SV SV2008002911A patent/SV2009002911A/es unknown
- 2008-05-22 CR CR10012A patent/CR10012A/es not_active Application Discontinuation
-
2010
- 2010-10-22 US US12/910,146 patent/US20110033464A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0618893A2 (pt) | 2011-09-13 |
EP1951305A1 (en) | 2008-08-06 |
AU2006318583A1 (en) | 2007-05-31 |
JP2009516692A (ja) | 2009-04-23 |
CA2630115A1 (en) | 2007-05-31 |
KR20080071192A (ko) | 2008-08-01 |
US20110033464A1 (en) | 2011-02-10 |
RU2008118166A (ru) | 2009-12-27 |
CN101312744A (zh) | 2008-11-26 |
WO2007062040A1 (en) | 2007-05-31 |
US20070237758A1 (en) | 2007-10-11 |
NO20082133L (no) | 2008-06-16 |
CR10012A (es) | 2008-07-29 |
SV2009002911A (es) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088459A (es) | Formulaciones de proteina de fusion de inmunoglobulina | |
TN2012000023A1 (en) | Subcutaneous anti-her2 antibody formulation | |
BRPI0608342A2 (pt) | antìgenos recombinantes quiméricos de toxoplasma gondii | |
PE20090738A1 (es) | Formulaciones de anticuerpos | |
AR072058A1 (es) | Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas | |
CY1117727T1 (el) | Φαρμακευτικες συνθεσεις κλωστηριδιακης τοξινης σταθεροποιημενης χωρις πρωτεϊνη | |
SG144075A1 (en) | Protein stabilization formulations | |
CY1116285T1 (el) | Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
AR037971A1 (es) | Preparacion liofilizada que contiene un anticuerpo contra el receptor egf | |
MX2012006831A (es) | Formacion de anticuerpos. | |
ECSP077246A (es) | Formulaciones Estabilizadoras | |
TW200700092A (en) | Tigecycline compositions and methods of preparation | |
WO2009137778A3 (en) | Methods and compositions for genetically engineering clostridia species | |
BRPI0613362A8 (pt) | polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
AU4653301A (en) | Anti-freeze proteins, their production and use | |
BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
WO2006079722A3 (fr) | Compositions pour la lyophilisation de proteines | |
WO2007002149A3 (en) | Methods and compositions relating to a vaccine against prostate cancer | |
MX2021011530A (es) | Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. | |
WO2007008697A3 (en) | Compositions and methods for refolding of denatured proteins | |
AU2016204324A1 (en) | Antibody formulation | |
AR055442A1 (es) | Variantes de la egln2 y su uso enla prevencion o tratamiento de tromboembolias y cardiopatias isquemicas | |
TH137777A (th) | สูตรผสมของเพพทิบอดีบำบัดที่ผ่านการไลโอฟิไลซ์ |